Almirante continues to deepen its specialization in dermatology. This is reflected in 2025, as the company quadrupled its profits to €46.2 million thanks to its portfolio of biological treatments, compared to €10.1 million in 2024. Group sales exceeded €1 billion, specifically €1.108 billion, representing a 12.4% increase over the previous year. Total revenue was €1.114 billion, up 12.5%. Operating profit (EBITDA) reached €232.9 million, a 20.9% year-on-year increase, and the gross margin was 64.4%. The key driver of these results was dermatology sales in Europe, which increased by 25.6% to €608 million, the company reported in a statement on Monday.

Catalan pharmaceutical group Almirall turns the page and returns to profit in its 2024 results. The company left losses behind and made a profit of 10.1 million euros compared to the negative 38.5 million in the previous year, it reported in a statement on Monday. The company has explained that its profits were "moderately affected by minor impairments."